ES3050125T3 - Bromocriptine formulations - Google Patents

Bromocriptine formulations

Info

Publication number
ES3050125T3
ES3050125T3 ES23214280T ES23214280T ES3050125T3 ES 3050125 T3 ES3050125 T3 ES 3050125T3 ES 23214280 T ES23214280 T ES 23214280T ES 23214280 T ES23214280 T ES 23214280T ES 3050125 T3 ES3050125 T3 ES 3050125T3
Authority
ES
Spain
Prior art keywords
bromocriptine formulations
bromocriptine
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES23214280T
Other languages
English (en)
Spanish (es)
Inventor
Anthony Cinotta
Craig Michael Bowe
Paul Clark Stearns
Laura Jean Weston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veroscience LLC
Original Assignee
Veroscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veroscience LLC filed Critical Veroscience LLC
Application granted granted Critical
Publication of ES3050125T3 publication Critical patent/ES3050125T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES23214280T 2012-04-30 2013-04-29 Bromocriptine formulations Active ES3050125T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/460,452 US8431155B1 (en) 2012-04-30 2012-04-30 Bromocriptine formulations

Publications (1)

Publication Number Publication Date
ES3050125T3 true ES3050125T3 (en) 2025-12-19

Family

ID=48146046

Family Applications (4)

Application Number Title Priority Date Filing Date
ES23214280T Active ES3050125T3 (en) 2012-04-30 2013-04-29 Bromocriptine formulations
ES13721874T Active ES2755081T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES19191600T Active ES2902573T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES21203207T Active ES2972198T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES13721874T Active ES2755081T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES19191600T Active ES2902573T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina
ES21203207T Active ES2972198T3 (es) 2012-04-30 2013-04-29 Formulaciones de bromocriptina

Country Status (12)

Country Link
US (11) US8431155B1 (enExample)
EP (4) EP4342536B1 (enExample)
JP (1) JP6180515B2 (enExample)
KR (1) KR101593360B1 (enExample)
AR (1) AR091351A1 (enExample)
AU (3) AU2013256558B2 (enExample)
BR (1) BR112014027087B1 (enExample)
CA (1) CA2872300C (enExample)
ES (4) ES3050125T3 (enExample)
MX (2) MX363670B (enExample)
UY (1) UY34776A (enExample)
WO (1) WO2013165902A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20090137598A1 (en) 2007-06-21 2009-05-28 Veroscience, Llc Method of treating metabolic disorders and depression with dopamine receptor agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
RU2650636C2 (ru) 2012-05-03 2018-04-16 Янссен Сайенсиз Айрлэнд Юси Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
AU2017254650A1 (en) 2016-04-20 2018-11-15 Veroscience Llc Composition and method for treating metabolic disorders
US10426772B2 (en) 2016-05-16 2019-10-01 Regents Of The University Of Minnesota Use of ergot alkaloids as an anthelmintic agent
EP3697418B1 (en) 2017-10-18 2024-07-24 VeroScience LLC Improved bromocriptine formulations
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783469A (en) 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US4659715A (en) 1986-03-07 1987-04-21 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5731287A (en) 1988-05-10 1998-03-24 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5830895A (en) 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5344832A (en) 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5700800A (en) 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5585347A (en) 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5744477A (en) 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5668155A (en) 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US6004972A (en) 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5006526A (en) 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
IT1235053B (it) * 1989-04-07 1992-06-17 Poli Ind Chimica Spa Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5696128A (en) 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5565454A (en) 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
US5792748A (en) 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US20040077679A1 (en) 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20050054652A1 (en) 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
HUE036646T2 (hu) 2003-01-23 2018-07-30 Esperion Therapeutics Inc Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US8137994B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
EA011379B1 (ru) 2005-03-04 2009-02-27 Никомед Фарма Ас Способ получения кальциевых композиций в непрерывном псевдоожиженном слое
EP2404604B1 (en) * 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
KR101400064B1 (ko) * 2006-04-13 2014-05-27 니폰 조키 세야쿠 가부시키가이샤 건식 직타 속붕괴성 정제
WO2008127794A2 (en) 2007-04-13 2008-10-23 Dow Global Technologies Inc. Granular material for dosage forms
US20210401824A1 (en) 2007-06-21 2021-12-30 Veroscience Llc Parenteral Formulations of Dopamine Agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20090137598A1 (en) 2007-06-21 2009-05-28 Veroscience, Llc Method of treating metabolic disorders and depression with dopamine receptor agonists
US7631155B1 (en) 2007-06-30 2009-12-08 Emc Corporation Thin provisioning of a file system and an iSCSI LUN through a common mechanism
KR20100091944A (ko) * 2007-10-11 2010-08-19 주식회사 머젠스 나프토퀴논계 화합물의 미세화 입자를 포함하는 약제 조성물
EP3375437A1 (en) * 2009-06-05 2018-09-19 VeroScience LLC Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
BR112012031103A2 (pt) 2010-06-08 2017-06-20 Veroscience Llc método para tratar um paciente sofrendo de um distúrbio metabólico, método para tratar pelo menos um desarranjo não-metabólico em um paciente, método para tratar pelo menos em desarranjo metabólico e pelo menos em desarranjo não-metabólico em um paciente, método para tratar pelo menos uma doença vascular em um paciente e composição farmacêutica efetiva para tratar a síndrome metabólica, diabetes tipo 2, obesidade, ou pré-diabetes
EP2646032A4 (en) 2010-11-23 2014-04-30 Veroscience Llc THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND TYPE 2 DIABETES, ADIPOSITAS OR PREDICTES
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
US20150011554A1 (en) 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
AU2017254650A1 (en) 2016-04-20 2018-11-15 Veroscience Llc Composition and method for treating metabolic disorders
US20170340271A1 (en) 2016-05-26 2017-11-30 Veroscience Llc Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions
EP3697418B1 (en) 2017-10-18 2024-07-24 VeroScience LLC Improved bromocriptine formulations
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Also Published As

Publication number Publication date
US20240131026A1 (en) 2024-04-25
EP2844229A1 (en) 2015-03-11
US9993474B2 (en) 2018-06-12
BR112014027087B1 (pt) 2021-03-02
AU2013256558B2 (en) 2016-01-28
AR091351A1 (es) 2015-01-28
US20180263978A1 (en) 2018-09-20
US10307421B2 (en) 2019-06-04
HK1208173A1 (en) 2016-02-26
EP4342536C0 (en) 2025-10-01
AU2016202572A1 (en) 2016-05-19
KR101593360B1 (ko) 2016-02-11
MX2019003619A (es) 2019-07-18
BR112014027087A2 (pt) 2017-06-27
EP2844229B1 (en) 2019-09-11
US20140187560A1 (en) 2014-07-03
AU2018203021B2 (en) 2020-02-06
US9192576B2 (en) 2015-11-24
EP4342536A3 (en) 2024-06-26
MX2014013158A (es) 2015-07-14
AU2013256558A1 (en) 2014-12-18
EP4342536B1 (en) 2025-10-01
KR20150006461A (ko) 2015-01-16
ES2755081T3 (es) 2020-04-21
ES2972198T3 (es) 2024-06-11
JP2015515984A (ja) 2015-06-04
JP6180515B2 (ja) 2017-08-16
US10688094B2 (en) 2020-06-23
MX363670B (es) 2019-03-29
US11000522B2 (en) 2021-05-11
UY34776A (es) 2013-11-29
CA2872300A1 (en) 2013-11-07
US20210228576A1 (en) 2021-07-29
EP3960160B1 (en) 2023-12-06
EP3960160A1 (en) 2022-03-02
US8431155B1 (en) 2013-04-30
AU2018203021A1 (en) 2018-05-24
EP4342536A2 (en) 2024-03-27
US9700555B2 (en) 2017-07-11
US20200276193A1 (en) 2020-09-03
EP3620155A1 (en) 2020-03-11
ES2902573T3 (es) 2022-03-29
AU2016202572B2 (en) 2018-02-01
US9522117B2 (en) 2016-12-20
US20190343833A1 (en) 2019-11-14
US11666567B2 (en) 2023-06-06
WO2013165902A1 (en) 2013-11-07
EP3620155B1 (en) 2021-10-20
CA2872300C (en) 2016-08-16
US8613947B2 (en) 2013-12-24
US20170340632A1 (en) 2017-11-30
US20130287848A1 (en) 2013-10-31
US20170020871A1 (en) 2017-01-26
US20160038424A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
EP2935220A4 (en) PERI-carbinol
ES3050125T3 (en) Bromocriptine formulations
GB2506426B (en) Composition
PL2804487T3 (pl) Kompozycja
GB201216800D0 (en) Novel use
ZA201500519B (en) Composition
EP2878295A4 (en) COMPOSITION
GB201218954D0 (en) Composition
GB2498803B (en) Composition
GB2508825B (en) Composition
HRP20190326T1 (hr) Pripravak
GB201206035D0 (en) Composition
ZA201407419B (en) Composition
IL236357A0 (en) The composition of misoprostol
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201218195D0 (en) Composition
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
GB201311517D0 (en) Composition
GB201219383D0 (en) Composition
SG11201405751TA (en) Composition
GB201212463D0 (en) Novel use
GB201206178D0 (en) Formulations
GB201223526D0 (en) Composition
GB201223224D0 (en) Composition